SpyGlass Pharma Statistics

Total Valuation

SpyGlass Pharma has a market cap or net worth of $708.12 million. The enterprise value is $458.72 million.

Market Cap	708.12M
Enterprise Value	458.72M

Important Dates

The next estimated earnings date is Monday, August 10, 2026, before market open.

Earnings Date	Aug 10, 2026
Ex-Dividend Date	n/a

Share Statistics

SpyGlass Pharma has 33.43 million shares outstanding.

Current Share Class	33.43M
Shares Outstanding	33.43M
Shares Change (YoY)	n/a
Shares Change (QoQ)	+807.79%
Owned by Insiders (%)	4.28%
Owned by Institutions (%)	16.00%
Float	6.48M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.83
P/TBV Ratio	2.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 38.00, with a Debt / Equity ratio of 0.01.

Current Ratio	38.00
Quick Ratio	37.75
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-19.64%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$659,765
Employee Count	68
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	21.46
200-Day Moving Average	n/a
Relative Strength Index (RSI)	57.88
Average Volume (20 Days)	150,012

Short Selling Information

The latest short interest is 1.01 million, so 3.03% of the outstanding shares have been sold short.

Short Interest	1.01M
Short Previous Month	1.14M
Short % of Shares Out	3.03%
Short % of Float	15.61%
Short Ratio (days to cover)	15.70

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-49.44M
Pretax Income	-44.86M
Net Income	-44.86M
EBITDA	-48.63M
EBIT	-49.44M
Earnings Per Share (EPS)	-$6.75

Full Income Statement

Balance Sheet

The company has $251.00 million in cash and $1.61 million in debt, giving a net cash position of $249.40 million or $7.46 per share.

Cash & Cash Equivalents	251.00M
Total Debt	1.61M
Net Cash	249.40M
Net Cash Per Share	$7.46
Equity (Book Value)	250.11M
Book Value Per Share	7.48
Working Capital	246.70M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$38.04 million and capital expenditures -$1.30 million, giving a free cash flow of -$39.35 million.

Operating Cash Flow	-38.04M
Capital Expenditures	-1.30M
Depreciation & Amortization	806,000
Net Borrowing	n/a
Free Cash Flow	-39.35M
FCF Per Share	-$1.18

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

SpyGlass Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-6.34%
FCF Yield	-5.56%

Analyst Forecast

The average price target for SpyGlass Pharma is $45.00, which is 112.47% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$45.00
Price Target Difference	112.47%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1